flupentixol   Click here for help

GtoPdb Ligand ID: 948

Synonyms: cis flupenthixol | alpha-flupenthixol | flupenthixol
Approved drug
flupentixol is an approved drug
Compound class: Synthetic organic
Comment: The approved drug flupentixol (aka flupenthixol) is the cis form. Flupenthixol is not approved for marketing by US FDA, but is available in other countries. For the structure of the trans form please see our entry for trans-flupenthixol.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: flupentixol

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 52.01
Molecular weight 434.16
XLogP 4.42
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OCCN1CCN(CC1)CCC=C1c2ccccc2Sc2c1cc(cc2)C(F)(F)F
Isomeric SMILES OCCN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)C(F)(F)F
InChI InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-
Bioactivity Comments
Flupentixol is one of a number of drugs that are cationic amphiphilic in nature, for which anti-SARS-CoV-2 activity has been identified in drug repurposing screens. Tummino et al. (2021; bioRxiv preprint PMID: 33791693 target="_blank") suggest that this antiviral activity is most likely a result of the drug promoting phospholipidosis via disruption of lipid homeostasis.
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
D3 receptor Hs Antagonist Antagonist 9.0 pKi - 1
pKi 9.0 (Ki 1.1x10-9 M) [1]
D2 receptor Primary target of this compound Hs Antagonist Antagonist 8.8 pKi - 1
pKi 8.8 (Ki 1.5x10-9 M) [1]
D5 receptor Hs Antagonist Antagonist 8.1 pKi - 2
pKi 8.1 [2]
D1 receptor Primary target of this compound Hs Antagonist Antagonist 7.0 – 8.4 pKi - 2-3
pKi 7.0 – 8.4 [2-3]
Description: Note that this assay uses the cis form of the compound, whereas the approved drug is a racemic mixture of cis and trans molecules.